Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Neven

Showing results (191-200 of 383) with videos related to

Pageof 39
Sort By:
Lymphatic Research and Biology|August 22, 2014
Reproducibility of lymphoscintigraphic evaluation of the upper limbNele Devoogdt, Tim Van den Wyngaert, Pierre Bourgeois, et al.
The Oncologist|March 29, 2014
Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancerBeverly Moy, Patrick Neven, Fabienne Lebrun, et al.
Breast Cancer Research : BCR|May 22, 2024
Reporting on patient's body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic reviewJosephine Van Cauwenberge, Karen Van Baelen, Marion Maetens, et al.
The Oncologist|June 10, 2026
Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancerJose Sandoval, Patrick Neven, Anna Emde, et al.
Cancer|January 22, 2008
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study resultsNigel J Bundred, Ian D Campbell, Neville Davidson, et al.
Menopause (New York, N.Y.)|July 10, 2003
Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 yearsElaine E Jolly, Nina H Bjarnason, Patrick Neven, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 6, 2019
Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumorsAn Coosemans, Thaïs Baert, Jolien Ceusters, et al.
The Oncologist|March 29, 2014
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancerBeverly Moy, Patrick Neven, Fabienne Lebrun, et al.
Breast Cancer Research : BCR|July 5, 2017
The footprint of the ageing stroma in older patients with breast cancerBarbara Brouwers, Debora Fumagalli, Sylvain Brohee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2022
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus FulvestrantSara M Tolaney, Masakazu Toi, Patrick Neven, et al.
Pageof 39

Showing results (191-200 of 383) with videos related to

Sort By:
Pageof 39
Lymphatic Research and Biology|August 22, 2014
Reproducibility of lymphoscintigraphic evaluation of the upper limbNele Devoogdt, Tim Van den Wyngaert, Pierre Bourgeois, et al.
The Oncologist|March 29, 2014
Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancerBeverly Moy, Patrick Neven, Fabienne Lebrun, et al.
Breast Cancer Research : BCR|May 22, 2024
Reporting on patient's body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic reviewJosephine Van Cauwenberge, Karen Van Baelen, Marion Maetens, et al.
The Oncologist|June 10, 2026
Navigating first- and second-line treatment options in HR+HER2-negative advanced breast cancerJose Sandoval, Patrick Neven, Anna Emde, et al.
Cancer|January 22, 2008
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study resultsNigel J Bundred, Ian D Campbell, Neville Davidson, et al.
Menopause (New York, N.Y.)|July 10, 2003
Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 yearsElaine E Jolly, Nina H Bjarnason, Patrick Neven, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 6, 2019
Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumorsAn Coosemans, Thaïs Baert, Jolien Ceusters, et al.
The Oncologist|March 29, 2014
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancerBeverly Moy, Patrick Neven, Fabienne Lebrun, et al.
Breast Cancer Research : BCR|July 5, 2017
The footprint of the ageing stroma in older patients with breast cancerBarbara Brouwers, Debora Fumagalli, Sylvain Brohee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2022
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus FulvestrantSara M Tolaney, Masakazu Toi, Patrick Neven, et al.
Pageof 39